Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans.

Bowman JC, Abruzzo GK, Flattery AM, Gill CJ, Hickey EJ, Hsu MJ, Kahn JN, Liberator PA, Misura AS, Pelak BA, Wang TC, Douglas CM.

Antimicrob Agents Chemother. 2006 Dec;50(12):4202-5. Epub 2006 Oct 2.

2.

Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.

Pelak BA, Citron DM, Motyl M, Goldstein EJ, Woods GL, Teppler H.

J Antimicrob Chemother. 2002 Nov;50(5):735-41.

PMID:
12407133
3.

Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections.

Pelak BA, Woods GL, Teppler H, Friedland I, Bartizal K, Motyl M.

J Chemother. 2002 Jun;14(3):227-33.

PMID:
12120874
4.
5.

Reduced immunotoxicity and preservation of antibacterial activity in a releasable side-chain carbapenem antibiotic.

Rosen H, Hajdu R, Silver L, Kropp H, Dorso K, Kohler J, Sundelof JG, Huber J, Hammond GG, Jackson JJ, Gill CJ, Thompson R, Pelak BA, Epstein-Toney JH, Lankas G, Wilkening RR, Wildonger KJ, Blizzard TA, DiNinno FP, Ratcliffe RW, Heck JV, Kozarich JW, Hammond ML.

Science. 1999 Jan 29;283(5402):703-6.

6.

In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).

Gill CJ, Jackson JJ, Gerckens LS, Pelak BA, Thompson RK, Sundelof JG, Kropp H, Rosen H.

Antimicrob Agents Chemother. 1998 Aug;42(8):1996-2001.

7.

Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H.

Antimicrob Agents Chemother. 1997 Nov;41(11):2339-44.

8.

Antibacterial agents that inhibit lipid A biosynthesis.

Onishi HR, Pelak BA, Gerckens LS, Silver LL, Kahan FM, Chen MH, Patchett AA, Galloway SM, Hyland SA, Anderson MS, Raetz CR.

Science. 1996 Nov 8;274(5289):980-2.

PMID:
8875939
9.

(Acyloxy)alkyl carbamate prodrugs of norfloxacin.

Alexander J, Fromtling RA, Bland JA, Pelak BA, Gilfillan EC.

J Med Chem. 1991 Jan;34(1):78-81.

PMID:
1992156
10.

L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals.

Gilfillan EC, Pelak BA, Weissberger BA, Abruzzo GK, Fromtling RA, Bland JA, Hadley SK, Gadebusch HH.

J Antibiot (Tokyo). 1989 May;42(5):815-22.

12.

L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy.

Gilfillan EC, Pelak BA, Fromtling RA, Bland J, Hadley S, Gadebusch HH.

J Antibiot (Tokyo). 1988 Aug;41(8):1137-41.

13.

Difficidin and oxydifficidin: novel broad spectrum antibacterial antibiotics produced by Bacillus subtilis. II. Isolation and physico-chemical characterization.

Wilson KE, Flor JE, Schwartz RE, Joshua H, Smith JL, Pelak BA, Liesch JM, Hensens OD.

J Antibiot (Tokyo). 1987 Dec;40(12):1682-91.

14.

Difficidin and oxydifficidin: novel broad spectrum antibacterial antibiotics produced by Bacillus subtilis. I. Production, taxonomy and antibacterial activity.

Zimmerman SB, Schwartz CD, Monaghan RL, Pelak BA, Weissberger B, Gilfillan EC, Mochales S, Hernandez S, Currie SA, Tejera E, et al.

J Antibiot (Tokyo). 1987 Dec;40(12):1677-81.

15.
16.

Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice.

Fromtling RA, Abruzzo GK, Gilfillan EC, Pelak BA, Gadebusch HH.

J Antimicrob Chemother. 1985 Dec;16(6):735-41.

PMID:
3912365
17.

Pharmacokinetic studies of norfloxacin in laboratory animals.

Gilfillan EC, Pelak BA, Bland JA, Malatesta PF, Gadebusch HH.

Chemotherapy. 1984;30(5):288-96.

PMID:
6237890
18.
19.
20.

In vivo inoculum effect and resistance selection with cefamandole and cefoxitin against Enterobacter cloacae in mice.

Miller AK, Celozzi E, Pelak BA, Birnbaum J, Stapley EO.

J Antimicrob Chemother. 1980 Nov;6(6):804-6. No abstract available.

PMID:
7002900
21.

Correlation of in vitro susceptibility with in vivo efficacy in mice for cefoxitin in comparison with cephalosporins.

Miller AK, Celozzi E, Pelak BA, Birnbaum J, Stapley EO.

J Antimicrob Chemother. 1979 Sep;5(5):569-79.

PMID:
315403
22.

The enhancement of beta-lactam antibiotic therapy by novobiocin.

Miller AK, Celozzi E, Pelak BA.

J Antibiot (Tokyo). 1977 Nov;30(11):983-6.

23.

Cefoxitin, a semisynthetic cephamycin antibiotic: in vivo evaluation.

Miller AK, Celozzi E, Kong Y, Pelak BA, Hendlin D, Stapley EO.

Antimicrob Agents Chemother. 1974 Jan;5(1):33-7.

24.

Cephamycins, a new family of beta-lactam antibiotics. IV. In vivo studies.

Miller AK, Celozzi E, Kong Y, Pelak BA, Kropp H, Stapley EO, Hendlin D.

Antimicrob Agents Chemother. 1972 Oct;2(4):287-90.

25.

Cephamycins, a new family of beta-lactam antibiotics. 3. In vitro studies.

Miller AK, Celozzi E, Pelak BA, Stapley EO, Hendlin D.

Antimicrob Agents Chemother. 1972 Oct;2(4):281-6.

Supplemental Content

Loading ...
Support Center